Skip to content
Screener

10x Genomics, Inc. TXG Change in fair value

Change in fair value at other companies

Mirum Pharmaceuticals, Inc. logo
Mirum Pharmaceuticals, Inc.MIRM
-$12.16M—
Mirum Pharmaceuticals, Inc. logo
Mirum Pharmaceuticals, Inc.MIRM
-$12.16M—
Asset Entities logo
Asset EntitiesASST
$0—
Asset Entities logo
Asset EntitiesASST
-$5.96M—
Asset Entities logo
Asset EntitiesASST
$0—
Enova International logo
Enova InternationalENVA
$360.86M+11.9%

Other financials

Income statement

See full
Revenue$151.0M-12.6%
Gross profit$112.5M-10.1%
Operating income-$19.6M-165%
Net income-$17.9M-152%
EPS (diluted)-$0.14-150%

Balance sheet

See full
Cash & equivalents$502.5M+26.4%
Total debt$78.8M-9.2%
Total equity$825.5M+6.8%
Total assets$1.0B+5.1%

Cash flow

See full
Operating cash flow$17.0M-4.1%
CapEx$1.6M+0.6%
Free cash flow$15.4M-4.6%

Valuation

See full
Market cap$6.61B+331%
Enterprise value$6.18B+406%
P/S10.7×+8.3×

Profitability

See full
Gross margin70%+0.5pp
Operating margin-14.3%-1.1pp
Net margin-12.2%-0.8pp
FCF margin19.7%+10.9pp

Returns & leverage

See full
Return on equity-9.4%-1.4pp
Debt / equity0.1×0.0×
Current ratio5.7×-0.1×

Where this comes from

Reported directly by 10x Genomics, Inc. in its filing.

Tagged under the XBRL concept txg:AssetAcquisitionGainLossContingentConsiderationChangeInFairValueDisclosure.

The source filing: 10x Genomics, Inc.’s 10-Q, filed August 7, 2026. Open the filing →

Filed
Aug 6, 2026, 8:00 PM EDT
Fiscal quarter
Q2 FY2026
Calendar quarter
Q2 2026
Accession
0001628280-26-054491

FAQ

What is 10x Genomics, Inc.'s change in fair value?
10x Genomics, Inc. (TXG) reported change in fair value of -$3.52M in Q2 2026.
What does change in fair value mean?
Change in fair value as reported by 10x Genomics, Inc. Class A Common Stock.

Ask your AI about 10x Genomics, Inc.'s change in fair value.

Connect your AI assistant and compare it to peers, right in your chat.

Connect your AI
Harbor at dusk
Claude